Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
Muthiah Vaduganathan(Harvard University), Scott D. Solomon(Brigham and Women's Hospital), John J.V. McMurray(Western Infirmary), Faı̈ez Zannad(Inserm), Milton Packer(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Gregg C. Fonarow, Jonathan W. Cunningham(Broad Institute), Brian Claggett(National Heart Lung and Blood Institute), João Pedro Ferreira(Inserm), Pardeep S. Jhund(Copenhagen University Hospital)
Cited by 645
Related Papers
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k